ITMI20002358A1 - Derivati di tieno ,2, 3-c|isochinolin-3-one come inibitori della poli(a dp-ribosio)polimerasi - Google Patents

Derivati di tieno ,2, 3-c|isochinolin-3-one come inibitori della poli(a dp-ribosio)polimerasi

Info

Publication number
ITMI20002358A1
ITMI20002358A1 IT002358A ITMI20002358A ITMI20002358A1 IT MI20002358 A1 ITMI20002358 A1 IT MI20002358A1 IT 002358 A IT002358 A IT 002358A IT MI20002358 A ITMI20002358 A IT MI20002358A IT MI20002358 A1 ITMI20002358 A1 IT MI20002358A1
Authority
IT
Italy
Prior art keywords
derivatives
ribose
polymerase
inhibitors
poly
Prior art date
Application number
IT002358A
Other languages
English (en)
Inventor
Flavio Moroni
Roberto Pellicciari
Original Assignee
Flavio Moroni
Roberto Pellicciari
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Flavio Moroni, Roberto Pellicciari filed Critical Flavio Moroni
Priority to IT002358A priority Critical patent/ITMI20002358A1/it
Publication of ITMI20002358A0 publication Critical patent/ITMI20002358A0/it
Priority to EP01980788A priority patent/EP1332147A1/en
Priority to PCT/IB2001/002030 priority patent/WO2002036599A1/en
Priority to EP04076527A priority patent/EP1464646B1/en
Priority to DE60140086T priority patent/DE60140086D1/de
Priority to US10/415,601 priority patent/US6989388B2/en
Priority to AT04076527T priority patent/ATE444298T1/de
Priority to AU2002212575A priority patent/AU2002212575A1/en
Priority to JP2002539357A priority patent/JP4417622B2/ja
Priority to ES04076527T priority patent/ES2332588T3/es
Publication of ITMI20002358A1 publication Critical patent/ITMI20002358A1/it
Priority to US11/264,468 priority patent/US7825129B2/en
Priority to US12/938,163 priority patent/US20110237617A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IT002358A 2000-10-31 2000-10-31 Derivati di tieno ,2, 3-c|isochinolin-3-one come inibitori della poli(a dp-ribosio)polimerasi ITMI20002358A1 (it)

Priority Applications (12)

Application Number Priority Date Filing Date Title
IT002358A ITMI20002358A1 (it) 2000-10-31 2000-10-31 Derivati di tieno ,2, 3-c|isochinolin-3-one come inibitori della poli(a dp-ribosio)polimerasi
ES04076527T ES2332588T3 (es) 2000-10-31 2001-10-30 Tieno(2,3-c)isoquinolinas para usar como inhibidores de parp.
DE60140086T DE60140086D1 (de) 2000-10-31 2001-10-30 Thieno(2,3-c)isoquinolinen zur Verwendung als Parp-Inhibitoren
PCT/IB2001/002030 WO2002036599A1 (en) 2000-10-31 2001-10-30 Thieno[2,3-c]isoquinolines for use as inhibitors of parp
EP04076527A EP1464646B1 (en) 2000-10-31 2001-10-30 Thieno(2,3-C) Isoquinolines for use as inhibitors of Parp
EP01980788A EP1332147A1 (en) 2000-10-31 2001-10-30 Thieno[2,3-c isoquinolines for use as inhibitors of parp
US10/415,601 US6989388B2 (en) 2000-10-31 2001-10-30 Thieno[2,3-c]iosquinolines for use as inhibitors of PARP
AT04076527T ATE444298T1 (de) 2000-10-31 2001-10-30 Thieno(2,3-c)isoquinolinen zur verwendung als parp-inhibitoren
AU2002212575A AU2002212575A1 (en) 2000-10-31 2001-10-30 Thieno(2,3-c)isoquinolines for use as inhibitors of parp
JP2002539357A JP4417622B2 (ja) 2000-10-31 2001-10-30 Ｐａｒｐの阻害剤として用いるためのチエノ［２，３−ｃ］イソキノリン
US11/264,468 US7825129B2 (en) 2000-10-31 2005-11-01 Thieno[2,3-c] isoquinolines for use as inhibitors of PARP
US12/938,163 US20110237617A1 (en) 2000-10-31 2010-11-02 Thieno[2,3-c] isoquinolines for use as inhibitors of parp

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT002358A ITMI20002358A1 (it) 2000-10-31 2000-10-31 Derivati di tieno ,2, 3-c|isochinolin-3-one come inibitori della poli(a dp-ribosio)polimerasi

Publications (2)

Publication Number Publication Date
ITMI20002358A0 ITMI20002358A0 (it) 2000-10-31
ITMI20002358A1 true ITMI20002358A1 (it) 2002-05-01

Family

ID=11446071

Family Applications (1)

Application Number Title Priority Date Filing Date
IT002358A ITMI20002358A1 (it) 2000-10-31 2000-10-31 Derivati di tieno ,2, 3-c|isochinolin-3-one come inibitori della poli(a dp-ribosio)polimerasi

Country Status (9)

Country Link
US (3) US6989388B2 (it)
EP (2) EP1332147A1 (it)
JP (1) JP4417622B2 (it)
AT (1) ATE444298T1 (it)
AU (1) AU2002212575A1 (it)
DE (1) DE60140086D1 (it)
ES (1) ES2332588T3 (it)
IT (1) ITMI20002358A1 (it)
WO (1) WO2002036599A1 (it)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20002358A1 (it) * 2000-10-31 2002-05-01 Flavio Moroni Derivati di tieno ,2, 3-c|isochinolin-3-one come inibitori della poli(a dp-ribosio)polimerasi
US6956035B2 (en) * 2001-08-31 2005-10-18 Inotek Pharmaceuticals Corporation Isoquinoline derivatives and methods of use thereof
EA011211B1 (ru) 2003-11-20 2009-02-27 Янссен Фармацевтика Н. В. 7-фенилалкилзамещённые 2-хинолиноны и 2-хиноксалиноны в качестве ингибиторов поли(адф-рибоза)полимеразы
AU2004295058B9 (en) 2003-11-20 2011-06-30 Janssen Pharmaceutica N.V. 6-alkenyl and 6-phenylalkyl substituted 2-quinolinones and 2-quinoxalinones as poly(ADP-ribose) polymerase inhibitors
JP4852540B2 (ja) 2004-06-30 2012-01-11 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Ｐａｒｐ阻害剤としてのフタラジン誘導体
SG154432A1 (en) 2004-06-30 2009-08-28 Janssen Pharmaceutica Nv Quinazolinedione derivatives as parp inhibitors
WO2006003150A1 (en) 2004-06-30 2006-01-12 Janssen Pharmaceutica N.V. Substituted 2-alkyl quinazolinone derivatives as parp inhibitors
RU2447889C2 (ru) * 2005-07-18 2012-04-20 Бипар Сайенсиз, Инк. Способ лечения рака (варианты)
US20070292883A1 (en) * 2006-06-12 2007-12-20 Ossovskaya Valeria S Method of treating diseases with PARP inhibitors
US20100279327A1 (en) * 2006-06-12 2010-11-04 Bipar Sciences, Inc. Method of treating diseases with parp inhibitors
US20080262062A1 (en) * 2006-11-20 2008-10-23 Bipar Sciences, Inc. Method of treating diseases with parp inhibitors
GB0615809D0 (en) * 2006-08-09 2006-09-20 Istituto Di Ricerche D Biolog Therapeutic compounds
CA2662337A1 (en) * 2006-09-05 2008-03-13 Bipar Sciences, Inc. Inhibition of fatty acid synthesis by parp inhibitors and methods of treatment thereof
CN101522609A (zh) * 2006-09-05 2009-09-02 彼帕科学公司 癌症的治疗
GB0701273D0 (en) * 2007-01-24 2007-02-28 Angeletti P Ist Richerche Bio New compounds
US20090006458A1 (en) * 2007-02-16 2009-01-01 Stivoric John M Life bytes
HRP20120346T1 (hr) 2007-03-08 2012-05-31 Janssen Pharmaceutica N.V. Derivati kinolinona kao parp i tank inhibitori
EP2207548B1 (en) * 2007-10-09 2013-05-22 Malka Cohen-Armon Breast cancer therapy
US9486449B2 (en) 2007-10-09 2016-11-08 Malka COHEN-ARMON Cancer therapy
PL2215075T3 (pl) 2007-10-26 2014-04-30 Janssen Pharmaceutica Nv Pochodne chinolinonu jako inhibitory PARP
JP2011503111A (ja) * 2007-11-12 2011-01-27 バイパー サイエンシズ，インコーポレイティド Ｐａｒｐ阻害剤単独又は抗腫瘍剤との組み合わせによる乳がんの治療
CA2705417A1 (en) * 2007-11-12 2009-05-22 Bipar Sciences, Inc. Treatment of uterine cancer and ovarian cancer with a parp inhibitor alone or in combination with anti-tumor agents
KR20100102637A (ko) * 2007-12-07 2010-09-24 바이파 사이언스 인코포레이티드 토포이소머라제 억제제 및 ｐａｒｐ 억제제의 병용물에 의한 암의 치료
US20090275608A1 (en) * 2008-02-04 2009-11-05 Bipar Sciences, Inc. Methods of diagnosing and treating parp-mediated diseases
JP5492183B2 (ja) 2008-03-27 2014-05-14 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Ｐａｒｐおよびチューブリン重合阻害剤としてのテトラヒドロフェナントリジノンおよびテトラヒドロシクロペンタキノリノン
AU2009228945B2 (en) 2008-03-27 2013-05-02 Janssen Pharmaceutica Nv Quinazolinone derivatives as tubulin polymerization inhibitors
CA2728466A1 (en) 2008-06-19 2009-12-23 Wyeth Llc Thienyl- and furanyl-isoquinolinones and methods for using them
SA109300394B1 (ar) * 2008-06-19 2013-01-22 ويث ثيازوليل- وأوكسازوليل- أيزوكوينولينونات وطرق لاستخدامها
WO2011058367A2 (en) 2009-11-13 2011-05-19 Astrazeneca Ab Diagnostic test for predicting responsiveness to treatment with poly(adp-ribose) polymerase (parp) inhibitor
CN103130723B (zh) 2011-11-30 2015-01-14 成都地奥制药集团有限公司 一种多聚(adp-核糖)聚合酶抑制剂
MX385227B (es) 2012-01-20 2025-03-14 Del Mar Pharmaceuticals Uso de hexitoles sustituidos que incluyen dianhidrogalactitol y análogos para tratar enfermedad neoplásica y células madre de cáncer que incluyen glioblastoma multiforme y meduloblastoma.
EP2983674A4 (en) 2013-04-08 2017-05-10 Dennis M. Brown Therapeutic benefit of suboptimally administered chemical compounds
CA2928568A1 (en) 2013-07-26 2015-01-29 Update Pharma Inc. Combinatorial methods to improve the therapeutic benefit of bisantrene
JP6783224B2 (ja) 2014-04-04 2020-11-11 デル マー ファーマシューティカルズ 肺の非小細胞癌腫及び卵巣癌を処置するためのジアンヒドロガラクチトール及びその類縁体又は誘導体の使用
ES2879434T3 (es) 2015-07-23 2021-11-22 Inst Curie Uso de una combinación de molécula Dbait e inhibidores de PARP para tratamiento del cáncer
GB201519573D0 (en) 2015-11-05 2015-12-23 King S College London Combination
WO2018022851A1 (en) 2016-07-28 2018-02-01 Mitobridge, Inc. Methods of treating acute kidney injury
RU2019114863A (ru) 2016-11-02 2020-12-03 Иммуноджен, Инк. Комбинированное лечение конъюгатами антитело-лекарственное средство и ингибиторами parp
WO2018162439A1 (en) 2017-03-08 2018-09-13 Onxeo New predictive biomarker for the sensitivity to a treatment of cancer with a dbait molecule
CA3096127A1 (en) 2017-04-28 2018-11-01 Akribes Biomedical Gmbh A parp inhibitor in combination with a glucocorticoid and/or ascorbic acid and/or a protein growth factor for the treatment of impaired wound healing
KR20200130856A (ko) 2018-03-13 2020-11-20 옹쎄오 암 치료에서 획득한 내성에 대한 디베이트 분자
JP7798358B2 (ja) 2019-11-25 2026-01-14 ザ・リサーチ・ファウンデーション・フォア・ザ・ステイト・ユニバーシティー・オブ・ニューヨーク 癌の処置のためにタキサンと共にｆａｂｐ５阻害剤を使用する併用療法
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
CN121398822A (zh) 2023-06-21 2026-01-23 四方生物科学有限公司 用于在治疗hr功能正常的癌症的方法中的用途的包含脱氧胞苷衍生物和parp抑制剂的组合

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1054655B (it) * 1975-08-27 1981-11-30 Lepetit Spa Derivati condensati del l isochinolina
US4263304A (en) * 1978-06-05 1981-04-21 Sumitomo Chemical Company, Limited 7 H-indolo[2,3-c]isoquinolines
US6358975B1 (en) 1997-08-15 2002-03-19 Johns Hopkins University Method of using selective parp inhibitors to prevent or treat neurotoxicity
US6514983B1 (en) * 1997-09-03 2003-02-04 Guilford Pharmaceuticals Inc. Compounds, methods and pharmaceutical compositions for treating neural or cardiovascular tissue damage
CA2332239A1 (en) * 1998-05-15 1999-11-25 Guilford Pharmaceuticals Inc. Fused tricyclic compounds which inhibit parp activity
ITMI20002358A1 (it) * 2000-10-31 2002-05-01 Flavio Moroni Derivati di tieno ,2, 3-c|isochinolin-3-one come inibitori della poli(a dp-ribosio)polimerasi

Also Published As

Publication number Publication date
ES2332588T3 (es) 2010-02-09
US20110237617A1 (en) 2011-09-29
US20060094746A1 (en) 2006-05-04
WO2002036599A1 (en) 2002-05-10
ITMI20002358A0 (it) 2000-10-31
JP2004520273A (ja) 2004-07-08
EP1464646B1 (en) 2009-09-30
AU2002212575A1 (en) 2002-05-15
ATE444298T1 (de) 2009-10-15
EP1332147A1 (en) 2003-08-06
EP1464646A1 (en) 2004-10-06
JP4417622B2 (ja) 2010-02-17
US7825129B2 (en) 2010-11-02
US20040082789A1 (en) 2004-04-29
US6989388B2 (en) 2006-01-24
DE60140086D1 (de) 2009-11-12

Similar Documents

Publication Publication Date Title
AU2002212575A1 (en) Thieno(2,3-c)isoquinolines for use as inhibitors of parp
TR200102005T2 (tr) Poli(adp-ribaz) polimerazların trisiklik inhibitörleri.
ATE407676T1 (de) Topoisomerasehemmern zur behandlung von chirurgischen verklebungen
EA200200306A1 (ru) Трициклические ингибиторы поли(адф-рибозо)полимераз
NO20054988D0 (no) Preparater og metoder for behandling av cancer
BR0011130A (pt) Inibidores de metaloproteases
IS2520B (is) Nikótínamíð afleiður nytsamlegar sem P38 hindrar
CY1110527T1 (el) Διαρυλ ενωσεις ως αναστολεις πρωτεασης σερινης
MY135766A (en) Quinolinones and naphthyridinones for treating inflammatory diseases
BG106406A (en) Pyrimidine-2,4,6-trione metalloproteinase inhibitors
CY1107531T1 (el) Χρηση αναστολεων πρωτεασομης για την αγωγη των διαταραχων ξηρου οφθαλμου
NO20032636D0 (no) 3-indolinderivater som er nyttige i behandlingen av psykiatriske og nevrologiske forstyrrelser
DE60121345D1 (de) Alkylierte imidazopyridinderivate
TR200401316T4 (tr) Proliferatif hastalıkları tedavi etmek için yöntemler ve bileşikler
AR034343A1 (es) Combinaciones farmaceuticas
ATE316954T1 (de) N-biphenylmethylaminocycloalkancarboxamid- derivative
MXPA04004372A (es) Derivados heterociclicos de glicinamida y su uso medico.
DE60115466D1 (de) Wirkstoffvorläufer von imidazopyridin-derivaten
AR024380A1 (es) Tienopirimidinas
DE60305053D1 (de) Pyrimidinderivate als selektive cox-2-inhibitoren
TR200302134T4 (tr) 2-metil-tiazolidin-2,4-dikarboksilik asit ve/veya bunun fizyolojik olarak uygun tuzlarının anti-kanser ajanları olarak kullanımı.
ATE381568T1 (de) Pyrano(2,3-c)imidazo(1,2-a)pyridin-derivate zur behandlung von gastrointestinalen erkrankungen
DK1292290T3 (da) Kombineret terapi mod tumorer omfattende substitueret acryloyl distamycinderivater og topoisomerase I og II inhibitorer
ATE335742T1 (de) Carbolinderivate als pdev inhibitoren
GB0319037D0 (en) 7-Azaindole Derivatives